GERD evaluation: Time for a new paradigm?

Journal of Clinical Gastroenterology

Volumn 41, Issue 3, 2007, Pages 237-241

  Modlin, Irvin M ^a   Malfertheiner, Peter ^b   Hunt, Richard H ^c   Armstrong, David ^c   Holtmann, Gerald ^d   Quigley, Eamon M ^e   Spechler, Stuart J ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY COLLEGE CORK   (Ireland)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dyspepsia; Evaluation; GERD; NERD; ReQuest; Symptom

Indexed keywords

ESOPHAGUS ULCER; EVALUATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; PATIENT SELECTION; PH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REFLUX ESOPHAGITIS; REVIEW; SYMPTOM;

ENDOSCOPY, GASTROINTESTINAL; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 33847346880     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225693.69745.49     Document Type: Review

References (34)

1. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998;43:327-333.
2. El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126:1692-1699.
3. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstedt Contry, Minnesota. Gastroenterology. 1997;112:1448-1456.
4. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastrooesophageal reflux disease: a systematic review. Gut. 2005;54:710-717.
5. Haque M, Wyeth JW, Stace NH, et al. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J. 2000;113:178-181.
6. Lim SL, Goh WT, Lee JM, et al. Community Medicine GI Study Group. Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol. 2005;20:995-1001.
7. Bor S, Mandiracioglu A, Kitapcioglu G, et al. Gastroesophageal reflux disease in a low-income region in Turkey. Am J Gastroenterol. 2005;100:759-765.
8. Loffeld R, van der Putten AB. Rising incidence of reflux oesophagitis in patients undergoing upper gastrointestinal endoscopy. Digestion. 2003;68:141-144.
9. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
10. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005; 128: 771-778.
11. Aro P, Ronkainen J, Storskrubb T, et al. Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study. Scand J Gastroenterol. 2004;39:1280-1288.
12. Irvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut. 2004;53(suppl 4):35-39.
13. Bardhan KD, Stanghellini V, Armstrong D, et al. Evaluation of GERD symptoms during therapy: part I. Development of the new GERD questionnaire ReQuest™. Digestion. 2004;69:229-237.
14. Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol. 2003;98:2454-2459.
15. Smart HL, Nicholson DA, Atkinson M. Gastro-oesophageal reflux in the irritable bowel syndrome. Gut. 1986;27:1127-1131.
16. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of esophagitis: clinical and functional correlated and further validation of the Los Angeles classification. Gut. 1999;45:172-180.
17. McColl KE. When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut. 2005;54:1-3.
18. Dent J, Armstrong D, Delaney B, et al. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004;53(suppl 4):1-24.
19. Quigley EMM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol. 2004:18;695-706.
20. Kiesslich R, Neurath M, Galle P. Chromoendoscopy and magnifying endoscopy in patients with gastroesophageal reflux disease. Dig Dis. 2004;22:142-147.
21. Avidan B, Sonnenberg A, Schnell TG, et al. Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci. 2002;47:2565-2573.
22. Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol. 2001;96:2033-2040.
23. Hirano I. Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease - Bilitec, intraluminal impedance and Bravo capsule pH monitoring. Aliment Pharmacol Ther. 2006;23(suppl 1):12-24.
24. Fass R, Offman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as a 24-hour esophageal pH monitoring in diagnosing gastroesophageal reflux disease (GERD) in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther. 2000;14:389-396.
25. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024-1031.
26. Fraser A, Delaney B, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol. 2005;100:442-452.
27. Rothman M, Farup C, Stewart W, et al. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci. 2001;46:1540-1549.
28. Mathias SD, Castell DO, Elkin EP, et al. Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci. 1996;41:2123-2129.
29. Stanghellini V, Armstrong D, Mönnikes H, et al. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther. 2004;19:463-479.
30. Armstrong D, Mönnikes H, Bardhan KD, et al. The construction of a new evaluative GERD questionnaire - methods and state of the art. Digestion. 2004;70:71-78.
31. Mönnikes H, Bardhan KD, Stanghellini V, et al. Evaluation of GERD Symptoms during Therapy. Part II. Psychometric Evaluation and Validation of the New Questionnaire ReQuest™ in Erosive GERD. Digestion. 2004;69:238-244.
32. Bardhan KD, Stanghellini V, Armstrong D, et al. International validation of ReQuest™ in patients with endoscopy negative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:891-898.
33. Stanghellini V, Armstrong D, Mönnikes H, et al. Determination of ReQuest™-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion. 2005;71:145-151.
34. Achim A, Riddermann T, Pfaffenberger B, et al. Pantoprazole 40 mg is at least comparable to esomeprazole 40 mg in achieving endoscopically confirmed healing and symptom relief of gastroesophageal reflux disease (GERD) after 4, 8 and 12 weeks of treatment. Can J Gastroenterol. 2005;19(suppl C):DR.0038.